Post Reply
6261-6280 of 10899
Biosensors to derive two-thirds of revenue from stent business within a year
By Desmond Wong, Channel NewsAsia | Posted: 14 July 2008 2037 hrs
SINGAPORE : Heart stent maker Biosensors International is aiming to have its stent business account for two-thirds of its revenue within the next 12 months.
For a start, it is counting on recent approval by European regulators to give its stent products greater access to the European market.
Manufacturing heart stents has been a key business for Biosensors. But in the last quarter, stents made up only a fifth of Biosensor's US$12 million revenue.
Its new CEO, Michael Kleine, wants to bump that up to two-thirds within a year. Having scaled back its US operations, Biosensors is now looking at Asia and Europe.
Mr Kleine said, "We're focused right now... on gaining a strong market share in Europe within the next three years, and we peg that at 10 per cent market share. We also feel that we have every opportunity and should be the major market share player in Asia, and that includes China."
The firm's signature product is the Biomatrix biodegradable drug eluting stent.
The company estimates that the market for heart stents in Europe is US$1.4 billion, while in China, it could be up to US$800 million.
With medical giants like Johnson & Johnson and Boston Scientific in the stent market, Biosensors seems to have its work cut out for it. However, the firm is hoping to compete based on the performance of its product.
Mr Kleine said, "You do it with clinical-based marketing; in other words, you take your product and you put it up against the best. And then you go to the market place and you say, 'here's our product as compared to the best of the best'."
Biosensors expects Europe to be its biggest market in a year, making up 60 per cent of revenue, while Asia's share will be 40 per cent. - CNA/ms
By Desmond Wong, Channel NewsAsia | Posted: 14 July 2008 2037 hrs
SINGAPORE : Heart stent maker Biosensors International is aiming to have its stent business account for two-thirds of its revenue within the next 12 months.
For a start, it is counting on recent approval by European regulators to give its stent products greater access to the European market.
Manufacturing heart stents has been a key business for Biosensors. But in the last quarter, stents made up only a fifth of Biosensor's US$12 million revenue.
Its new CEO, Michael Kleine, wants to bump that up to two-thirds within a year. Having scaled back its US operations, Biosensors is now looking at Asia and Europe.
Mr Kleine said, "We're focused right now... on gaining a strong market share in Europe within the next three years, and we peg that at 10 per cent market share. We also feel that we have every opportunity and should be the major market share player in Asia, and that includes China."
The firm's signature product is the Biomatrix biodegradable drug eluting stent.
The company estimates that the market for heart stents in Europe is US$1.4 billion, while in China, it could be up to US$800 million.
With medical giants like Johnson & Johnson and Boston Scientific in the stent market, Biosensors seems to have its work cut out for it. However, the firm is hoping to compete based on the performance of its product.
Mr Kleine said, "You do it with clinical-based marketing; in other words, you take your product and you put it up against the best. And then you go to the market place and you say, 'here's our product as compared to the best of the best'."
Biosensors expects Europe to be its biggest market in a year, making up 60 per cent of revenue, while Asia's share will be 40 per cent. - CNA/ms
Just saw the brief TV interview - Biosensors hope to get 2/3 of their revenue from the stent business within a year.
Mathematically, if their existing non-stent business is US$40m, then the total projected revenue must be approx US120m, of which 2/3 will work out to a stent revenue of US$80m, which translate to US$20m per qtr !
wonder if the projected 2/3 of total revenue includes JWMS or not ?
Again, these are just assumptions - Do not want to raise hopes unrealistically - A first qtr revenue of US$6-8m in my view is good enough for a product that has just started commercialisation.
Not a call to buy/sell. - Technically, the trend still looks to be down,
Yo BRO you also know the TV schedule...
Channel News Asia will be interviewing BIG's new CEO Michael Kline tonight at 10.15pm in their business segment news. Tune in to listen what he has got to say. Maybe BIG will chiong tomorrow morning???
today u can buy lulian for 10 cts. BIG at .485 cts more or less an equivalent lewo. consider to be cheap leow, but no loose cap to acc for avg.
congrate for those sifus incubated this burger during pasar malam lelong period. cheers.
50cts first,,,,,,,,and the rest ask bb f gg,,,,,,,,,,,buy ur limited,,,,,,buy for long term,,,,,,,,,,,,,,buy for DOW JONES TUA CHIONG,,,,,,,,,,,,,,,TIME TO BUY TIS BABY,,,,,,,,,,I THING Q STRONG,,,,,,,,,,,,,I NOT GOING TO BUY MORE LIAO,,,,,,,,LET THE BB DO THEIR JOB,,,,,,BUT MAY WILL GO IN SEE FIRST
I also jeep some this morning. If today BIG can close at 48.5cts and above, that means 3 consecutive days of closing above their lowest close of 48.5cts on 10/07/08. In that case, the vicious cycle wave of margin call dumping will be broken and this stock should be out of ICU and transfered into normal patient ward. If this vicious cycle is broken, shortie has lesser reason to disturb this stock without "eastwind" assistance via margin call dumping. Hope im right on this analysis.
idesa168 ( Date: 14-Jul-2008 11:34) Posted:
|
ok bengster, I am back, jeep some for long term holding. Should be able to reap some profit at this price...let see! Cheers!
We can see that the recent resurging demand of DES could be due to the reduced impact of blood clot scare that the media has overplayed since Barcelona May 2006. DES players fought back with trials claiming DES is actually better than BMS. It is silly to revert back to using BMS. Recent pick up of DES use in USA market (up by almost 10% in 4 months) is most likely due to Endeavor's FDA approval. I expect to see even stronger pick up in DES demand over the whole of 2008 and 2009, possibly around 80% (demand up by another 15%) by end of 2008 because of Xience's recent FDA approval. Xience and Endeavor are touted to be safer than older generation DES like Cypher and Taxus and should rekindle the demand for DES. There should be a strong resurgence of using these 2 newly approved DES instead of BMS and older DESs over the next few years.
JNJ's new Cordis Group President Seth Fisher (took over Rick Anderson... i heard he kena sacked by JNJ HQ) said earlier this year that DES demand will growing at 1% a year at best. I think Seth Fisher can eat his own words now. Over the past 4 months the USA market for DES has turned upwards strongly at almost 10% growth and Asia DES market is experiencing huge exponential growth. He could be down playing JNJ's recent poor DES performance and recent Conor takeover misadventure in stent business. He could also be calling a bluff signal to BIG that JNJ is not really interested in stent business but in fact they are very desperate for BIG. Life is always a like Hollywood in USA. JNJ already made billions from DESs and was once the DES king. I don't think JNJ will allow their stent division to fall from formerly The Number One DES Player to zero. DES is still a highly lucrative medical product with current yearly global sales of US$5.4B and now growing back strongly again. How can JNJ afford to ignore this large market?
JNJ's new Cordis Group President Seth Fisher (took over Rick Anderson... i heard he kena sacked by JNJ HQ) said earlier this year that DES demand will growing at 1% a year at best. I think Seth Fisher can eat his own words now. Over the past 4 months the USA market for DES has turned upwards strongly at almost 10% growth and Asia DES market is experiencing huge exponential growth. He could be down playing JNJ's recent poor DES performance and recent Conor takeover misadventure in stent business. He could also be calling a bluff signal to BIG that JNJ is not really interested in stent business but in fact they are very desperate for BIG. Life is always a like Hollywood in USA. JNJ already made billions from DESs and was once the DES king. I don't think JNJ will allow their stent division to fall from formerly The Number One DES Player to zero. DES is still a highly lucrative medical product with current yearly global sales of US$5.4B and now growing back strongly again. How can JNJ afford to ignore this large market?
bengster68 ( Date: 14-Jul-2008 00:28) Posted:
|
i just forget to say that buy your limited,,,,,,,,,cheers,,,,,im going to bet tinite DOW JONES REVERSE STRONG RAILLY AFTER RESCUE PLAN KICK OFF,,,,,buy low buy badly hit by force selling,,,,,,,,,,,,,,,,,,,,,,,,,buy call when share botttoom going to chiong ,,,,,,,,cheers for better tomorow,,,,,,,,im still say that tis baby 50cts first,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Hello, what you do is your business, do'nt try to blow & lure other into your action. Keep it to yourself!!! Ha Ha Ha 
buy again,,,,,,,im miss china hongxing,,,,,,,so im going to put tis baby my flahship,,,,,,,chiong ah,,,,,,,,,my am remise also buy liao,,,,,come on bb from gg.............will see tis baby above 50cts first,,,,,,cheers
http://www.crtonline.org/flash.aspx?PAGE_ID=5587
The percentages reported are number of DES used in stenting procedures. Eg, in March 2008, the figure was 66.9% for DES. That means 33.1% of people choose to use BMS.
I am surprised by the resurging demand of DES which is much sooner than what most people in the DES industry expect. There is a distinct uptrend in DES usage in recent months for USA market. The DES market is clearly growing back after the recent late-thrombosis scare. With newer DES like Endeavor and Xience entering the USA market, i think the DES market has a good chance to recover back to almost the previous peak usage. Of course Biomatrix is the best answer to late-thrombosis scare because it has absolutely zero cases of occurance and reverts back to BMS after 6 months due to its biodegradable polymer. Looks like JNJ is the only player left out in this regrowth of DES demand. At least BSX still has got "Promus" to Chiam See Tong.
When LEADERS results are out, I will tabulate the ENDEAVOR III VS LEADERS results as both are RCTs against JNJ's Cypher. Then we can have an indirect comparision of Endeavor Vs Biomatrix!
Thanks bengster for this table. This results is for 9 months. I think the late catch up for Xience will further decrease some of the clear % gain shown in your table. I think a 24 months table will even show more glaring advantanges of biomatrix.
bengster68 ( Date: 13-Jul-2008 02:18) Posted:
|
I have managed to tabulate the results of various RCTs against Taxus's measurements.
Late-Loss Restenosis TLR TVR MACE Thrombosis
EndeavorIV: Up 60% Up 47% Up 41% Up 6% Down 2% Up 800%
Spirit III: Down 48% Down 47% Down 46% Down 29% Down 43% *Level %*
Nobori ph1: Down 53% *Both 0%* Down 100% *N.A* Down 59% *Both 0%*
Nobori ph2: Down 66% Down 87% Down 100% *N.A* Down 30% Down 100%
From the comparison of the above RCTs against Taxus on all the various end-point measurements at 9 months, we can clearly see that Biomatrix is the clear winner and Endeavor is clearly the worst among the Endeavor, Xience and Biomatrix. "Up" means % of increase against Taxus' measurements. "Down" means % of decrease against Taxus' meansurements. The lower the "Down" %, the better.
Spirit III is Xience Vs Taxus. Nobori 1 phase 1 is Biomatrix Vs Taxus. Nobori 1 phase 2 is Biomatrix Vs Taxus Liberte. Taxus Liberte is the latest version of Taxus DES and there are already trials done by Boston Scientific proving that Taxus Liberte is better than their earlier version called Taxus Express.
Absolutely no other DESs can even touch Biomatrix's performance. With stunning Biomatrix results, any medical device MNC that buy up this company will be definitely be the next DES leader for 10 good years. All the DES technology BIG has are proprietary, not licensed from any other company. These are the real value in BIG.
LOL i see lots of :rallying here...
If this can "yi tiao Xing" cont to August ...
Interesting counter to observe
=oP
IF you go to EUROPCRONLINE.COM or TCTMD.COM, and type 'Biolimus' or 'XTENT', you probably can get some slides of the animal data.
Currently, Bio-matrix, XTENT, and Nobori, uses a primer, Parylene-C, which I believe is only 5 microns thick, that is on the metal stent, and it has been used a lot on a lot of applications, very bio-compatible (Cypher also uses it).
Renu Virmani also did some tests on the Parylene-C, and she showed that there is good endothelialisation, with all the metal struts completely covered at 28 days.
THe difference between Parylene-C and a polymer is that it does not elute the drug, which is the primary function of the polymer.
ALso, I believe that the LEADERS trial has done away with Parylene-C, using only a pure metal stent, probably the bio-flex II, ie a nwer version of the S-stent.
Do you know if the animal studies done by Dr. Virmani on Biomatrix are available on line? I would love to see them. Although it sounds good, I am still uncertain as to the value of the absorbable polymer on Bio-matrix compared to the newer polymers on the Endeavor and Xience. I believe that there is a primer on the Bio-matrix stent to help secure the PLA polymer onto it. Does anyone know anything about this primer and is it permanent?
investor ( Date: 11-Jul-2008 09:31) Posted:
|
NEW YORK (Associated Press) - Shares of Xtent reversed course Thursday from prior day gains, after the medical device maker said it would slash 34 percent of its work force to cut costs as it seeks a new round of financing.
The stock fell 8 cents, or 2.6 percent, to $3 in midday trading, after falling as low as $2.75 earlier in the session. On Wednesday, shares jumped 18 percent as another Wall Street analyst added to the already bullish outlook on the company's developing drug-coated stent, Custom NX.
In a Securities and Exchange Commission filing Thursday, Xtent said it is cutting 47 regular jobs and 26 temporary positions to reduce costs. It plans to seek another round of financing in the second half of 2008.
The job cuts, which amount to about 34 percent of the company's staff, are expected to be complete this month. It will cost the company between $450,000 and $500,000, with most of the expenses coming in the third quarter. Average monthly savings from the job cuts and other cost-cutting initiatives could reach $1.3 million, Xtent said.
Along with the job cuts, Brian Walsh, vice president of sales and marketing, and Jeffry Grainger, vice president of corporate affairs and general counsel, resigned. The resignations are effective Friday.
"We believe this headcount reduction is prudent ahead of a capital raise that was already accounted for in our model," said Cowen and Co. analyst Sara Michelmore, in a note to investors.
She reaffirmed an "Outperform" rating for the stock, also stating that shares are likely undervalued based on the potential for the company's Custom NX stent.
"While the stock has struggled due to the shifting dynamics of the broader drug-eluted stent market, we continue to believe there is considerable value in Xtent's innovative Custom NX drug-eluting stent platform."
On Wednesday, RBC Capital Market's Phil Nabone reaffirmed a "Outperform" rating, also citing the stent's potential. The recent assessments echo bullish comments made over the past few months by several other analysts.
Stents are mesh-metal tubes used to prop open clogged arteries after they have been cleared of plaque, and drug coatings are used to prevent the growth of scar tissue. Wall Street has been hoping for a recovery in the drug-coated stent market after years of declines because of research questioning their safety and effectiveness.
